Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: Results of a bone marrow failure consortium study

Susan Bell Nyland, Daniel J. Krissinger, Michael J. Clemente, Rosalyn B. Irby, Kendall Thomas Baab, Nancy Ruth Jarbadan, Lubomir Sokol, Eric Schaefer, Jason Liao, David Cuthbertson, Pearlie Epling-Burnette, Ronald Paquette, Alan F. List, Jaroslaw P. Maciejewski, Thomas P. Loughran

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.

Original languageEnglish (US)
Pages (from-to)581-587
Number of pages7
JournalLeukemia Research
Volume36
Issue number5
DOIs
StatePublished - May 2012

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: Results of a bone marrow failure consortium study'. Together they form a unique fingerprint.

Cite this